Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 24:S1875-2136(25)00826-5.
doi: 10.1016/j.acvd.2025.10.331. Online ahead of print.

Allocation and prognosis of temporary mechanical circulatory support in unselected cardiogenic shock: Insights from the FRENSHOCK registry

Stéphane Manzo-Silberman  1 , Vincent Bataille  2 , Laurent Bonello  3 , François Roubille  4 , Bernard Levy  5 , Pascal Lim  6 , Guillaume Schurtz  7 , Philippe Letocart  8 , Karim Chaoui  9 , Vincent Probst  10 , Emile Ferrari  11 , Olivier Delhaye  12 , Raphael Favory  13 , Meyer Elbaz  14 , Edouard Gerbaud  15 , Eric Bonnefoy  16 , Etienne Puymirat  17 , Guillaume Leurent  18 , Clement Delmas  19
Affiliations
Free article

Allocation and prognosis of temporary mechanical circulatory support in unselected cardiogenic shock: Insights from the FRENSHOCK registry

Stéphane Manzo-Silberman et al. Arch Cardiovasc Dis. .
Free article

Abstract

Background: Patients in cardiogenic shock (CS) can benefit from temporary mechanical circulatory support (tMCS) but data in heterogeneous populations with diverse CS aetiologies are rare.

Aims: To compare baseline characteristics, management and independent correlates of 30-day and 1-year mortalities between patients managed with and without tMCS for CS.

Methods: The FRENSHOCK registry (NCT02703038) included 772 unselected patients with CS admitted in 49 French critical care units between April and October 2016.

Results: Among 770 patients with CS and available data, 135 (17.5%) received tMCS (63 extracorporeal life support, 35 intra-aortic balloon pump, 13 micro-axial flow pump and 24 combination), of whom 69.0% were implanted during the first 24hours. Patients with tMCS were less likely to present with histories of cardiac or peripheral artery diseases or chronic renal failure. An ischaemic or mechanical complication trigger for CS tripled the probability of receiving tMCS, while increased lactate doubled the probability. Thirty-day mortality was higher among patients with versus without tMCS (34.1% vs. 24.3%; P<0.001), but after adjustment for age and CS severity (LVEF and arterial lactates at admission, noradrenaline and invasive mechanical ventilation use), the difference was no longer significant (hazard ratio: 1.37, 95% confidence interval: 0.93-2.01). Among 30-day survivors, mortality was similar regardless of initial receipt of tMCS (P=0.312).

Conclusion: In real-life practice, tMCS may not be associated with improvements in 30-day or 1-year mortality in an all-comers cohort of patients with CS. However, it should be noted that there were substantial differences in patient characteristics and management between patients who received tMCS and those who did not. Additional targeted studies should help to determine more precise algorithms for granting assistance within the complex and heterogeneous population of patients with CS.

Keywords: Cardiogenic shock; Extracorporeal membrane oxygenation; Mechanical circulatory support; Microaxial flow pump; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure of interest S.M.-S. has received consulting fees from Bayer, Organon and Exeltis; lecture fees from Bayer, BMS, Exeltis and Organon; and has served on the adjudication board for a study for Biotronik. G.L. reports proctoring activity, lecture and consultant fees from Abbott Medical and Edwards Lifescience. E.G. reports, outside the submitted work, personal fees and/or non-financial support from Terumo, Novo Nordisk, Abbott Medical, Servier and AOP Orphan Pharmaceuticals France. C.D. has received consulting fees from Abiomed, Abbott and Moderna; lecture fees from Abiomed, Abott, AstraZeneca, Bayer, Orion and Servier. All authors declare that they have no competing interest.

LinkOut - more resources